Welcome to our dedicated page for Scisparc SEC filings (Ticker: SPRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SciSparc Ltd. (Nasdaq: SPRC) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer. SciSparc files annual reports on Form 20-F and frequent current reports on Form 6-K, which together describe its clinical-stage pharmaceutical activities, capital structure, and material corporate events.
Recent Form 6-K filings highlight several categories of information. Transaction-related 6-Ks describe agreements such as the asset and share purchase arrangement through which SciSparc obtained a controlling interest in NeuroThera Labs Inc. and transferred its advanced clinical-stage pharmaceutical portfolio and its stake in SciSparc Nutraceuticals Inc. to NeuroThera. Other 6-Ks detail the sale of MitoCareX Bio Ltd. to N2OFF, Inc., the binding term sheet and definitive agreement to acquire a treasury of patents and trademarks for the MUSE endoscopic system from Xylo Technologies Ltd., and a framework agreement terminating a prior merger agreement with AutoMax Motors Ltd. and setting loan repayment terms.
Filings also cover capital markets and compliance matters, including inducement letter agreements with holders of existing warrants, under which warrant exercise prices were adjusted and SciSparc expects to receive gross proceeds for working capital and general corporate purposes. Another 6-K reports a Nasdaq notification that the company no longer met the minimum stockholders’ equity requirement for continued listing, and outlines the timeframe to submit a compliance plan.
In addition, SciSparc uses Form 6-K to furnish financial statements and MD&A, such as unaudited consolidated interim financial statements and management’s discussion and analysis for the six months ended June 30, 2025. Patent- and R&D-related press releases—covering NeuroThera’s opioid–N-acylethanolamine patent, MEAI-based depression patent applications, and the quantum computing-enabled 3D protein modeling initiative—are also incorporated by reference via 6-K exhibits.
On this page, users can review SciSparc’s 6-K submissions, including exhibits like binding term sheets, asset and share purchase agreements, and inducement letters, alongside its 20-F annual report. AI-powered tools summarize key points from these filings, highlight items such as equity transactions, IP acquisitions, and listing status updates, and help readers navigate complex transaction terms and risk disclosures without reading every page in detail.
SciSparc Ltd. furnished a Form 6-K that provides its unaudited consolidated interim financial statements as of June 30, 2025, together with management’s discussion and analysis of financial condition and results of operations for the six months ended June 30, 2025.
The filing is incorporated by reference into SciSparc’s existing registration statements on Form F-3 and Form S-8, so these interim financials and related analysis become part of those offering documents from the submission date.
SciSparc Ltd. filed a prospectus supplement to update its F-4 prospectus with a Form 6-K detailing a new Framework Agreement with AutoMax Motors. The parties mutually terminated their prior merger agreement, rendering it null and void effective October 6, 2025.
The agreement sets specific loan repayments to SciSparc: AutoMax will repay a $4.25 million loan with 9% annual compound interest in a single lump-sum on January 1, 2028. A separate $2.0 million loan will be repaid in $60,000 monthly installments starting November 20, 2025, with 8% annual compound interest accruing to each payment date, plus $114,523 of accrued interest through November 20, 2025. The supplement incorporates the 6-K and attaches the Framework Agreement and related press release as exhibits.
SciSparc Ltd. (SPRC) reported it has closed the acquisition of a publicly traded company on the TSX Venture Exchange and transferred its advanced clinical‑stage pharmaceutical portfolio to that company. The announcement was furnished via a Form 6-K that also includes the related press release as an exhibit.
The Form 6-K is incorporated by reference into SciSparc’s effective registration statements on Forms F-3 and S-8, aligning the disclosure with its existing U.S. registration frameworks.
N2OFF, Inc. (NITO) reported an initial statement of beneficial ownership on Form 3. The filing shows the reporting person is a Director and directly holds 490,751 shares of common stock.
The event date for this ownership report is 10/20/2025. No derivative securities were listed in the submission.
SciSparc Ltd. (SPRC) closed the sale of its stake in MitoCareX to N2OFF on October 20, 2025. In exchange, SciSparc received a cash payment of $700,000 and 490,751 shares of N2OFF common stock, representing 16.75% of N2OFF on a fully diluted basis.
The transaction leaves N2OFF owning 100% of MitoCareX, while SciSparc now holds a meaningful equity position in N2OFF plus cash proceeds. The company also furnished a press release as Exhibit 99.1 detailing the closing and MitoCareX’s focus on drug discovery for resistant cancers.
SciSparc Ltd. entered into an asset and share purchase agreement to obtain a controlling interest in Miza III Ventures Inc. by transferring its pharmaceutical portfolio and approximately 50.9% of SciSparc Nutraceuticals Inc.
At closing, SciSparc will receive 63,300,000 Miza common shares at CAD 0.25 per share, 4,000,000 five‑year warrants at an exercise price of CAD 0.25, and up to 48,000,000 contingent shares upon milestones. This represents a post‑closing equity interest of 75% in Miza, or up to approximately 84% if all milestones are achieved. The transaction reflects a value of approximately CAD 4.5 million for Miza and approximately CAD 15.8 million for the transferred assets.
Miza is expected to be renamed NeuroThera Labs Inc. and operate in pharmaceutical and supplemental sectors. Completion is anticipated by October 22, 2025, subject to conditions, with no assurance of closing. Upon closing and TSXV approval, SciSparc also plans an unsecured convertible note of up to CAD 1 million at 7%, maturing in two years and convertible at CAD 0.25 per share up to 4,000,000 shares. The securities will be issued under exemptions from U.S. registration.
SciSparc Ltd. disclosed a framework agreement to merge with AutoMax Ltd. The agreement is described as dated October 6, 2025 and names SciSparc Merger Sub Ltd. as a party, indicating a planned transaction structure using a merger subsidiary. The company issued a press release titled "SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors." The filing includes an officer signature block listing Oz Adler as Chief Executive Officer and Chief Financial Officer. The disclosure conveys a strategic transaction is underway but provides only the agreement notice and the press release reference without terms, financial consideration, approvals, or closing conditions.
SciSparc Ltd. announced that N2OFF shareholders approved a merger with MitoCareX, SciSparc's majority-owned subsidiary. The press release states the transaction was approved and identifies MitoCareX as a drug discovery company focused on therapies for resistant cancers, specifically naming pancreatic cancer and non-small cell lung cancer. The filing is presented as a current report (Form 6-K) and is signed by Oz Adler as Chief Executive Officer and Chief Financial Officer on September 30, 2025. The release does not include financial terms, an effective merger date, or post-transaction ownership percentages.
SciSparc Ltd. entered into inducement letter agreements with holders of its existing warrants to purchase up to 361,548 ordinary shares. The holders agreed to exercise all of these warrants for cash at a reduced exercise price of $3.10 per share, down from $11.6172. SciSparc expects to receive approximately $1.12 million in gross proceeds from these cash exercises.
The closing of these transactions is expected on or about September 29, 2025, subject to customary closing conditions, and the company plans to use the net proceeds for working capital and general corporate purposes. The resale of the ordinary shares underlying these warrants was previously registered on an effective Form F-3 shelf registration statement.
SciSparc Ltd. disclosed the launch of an innovative quantum computing-enabled 3D protein modeling initiative intended to support AI-driven drug discovery. The report cites the program name and presents a company signature by Oz Adler as Chief Executive Officer and Chief Financial Officer on September 25, 2025. The filing attaches standard registration statement references but contains no financial results, funding details, partner names, timelines, or measurable milestones. This limits the ability to assess near-term commercial or revenue impact.